Literature DB >> 15155637

Age-specific immunoglobulin g (IgG) and IgA to pneumococcal protein antigens in a population in coastal kenya.

Catherine Laine1, Tabitha Mwangi, Claudette M Thompson, Jacktone Obiero, Marc Lipsitch, J Anthony G Scott.   

Abstract

Streptococcus pneumoniae is the primary etiological agent of community-acquired pneumonia and a major cause of meningitis and bacteremia. Three conserved pneumococcal proteins-pneumolysin, pneumococcal surface adhesin A (PsaA), and pneumococcal surface protein A (PspA)-are currently being investigated as vaccine candidates. Such protein-based vaccines, if proven effective, could provide a cheaper alternative to conjugate vaccine formulae. Few data from sub-Saharan Africa exist concerning the development of natural antibody to these antigens, however. To investigate the age-specific development of antiprotein immunoglobulin G (IgG) and IgA antibody responses, the sera of 220 persons 2 weeks to 84 years of age from coastal Kenya were assayed using enzyme-linked immunosorbent assays. IgG and IgA antibody responses to each antigen were observed in all age groups. Serum concentrations of IgG and IgA antibody responses to PspA and PdB (a recombinant toxoid derivative of pneumolysin), but not to PsaA, increased significantly with age (P < 0.001). No decline was observed in the sera of the elderly. Anti-protein IgG concentrations were only weakly correlated (0.30 < r < 0.56; P < 0.0001), as were IgA concentrations (0.24 < r < 0.54; P < 0.0001).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15155637      PMCID: PMC415695          DOI: 10.1128/IAI.72.6.3331-3335.2004

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  26 in total

1.  Prevention of pneumococcal pneumonia by vaccination.

Authors:  R Austrian; R M Douglas; G Schiffman; A M Coetzee; H J Koornhof; S Hayden-Smith; R D Reid
Journal:  Trans Assoc Am Physicians       Date:  1976

Review 2.  The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae.

Authors:  D E Briles; S K Hollingshead; G S Nabors; J C Paton; A Brooks-Walter
Journal:  Vaccine       Date:  2000-12-08       Impact factor: 3.641

3.  Spread of Streptococcus pneumoniae in families. I. Carriage rates and distribution of types.

Authors:  J O Hendley; M A Sande; P M Stewart; J M Gwaltney
Journal:  J Infect Dis       Date:  1975-07       Impact factor: 5.226

Review 4.  The potential indirect effect of conjugate pneumococcal vaccines.

Authors:  Katherine L O'Brien; Ron Dagan
Journal:  Vaccine       Date:  2003-05-16       Impact factor: 3.641

5.  Antibody response to the pneumococcal proteins pneumococcal surface adhesin A and pneumolysin in children with acute otitis media.

Authors:  S Rapola; T Kilpi; M Lahdenkari; P H Mäkelä; H Käyhty
Journal:  Pediatr Infect Dis J       Date:  2001-05       Impact factor: 2.129

6.  Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA.

Authors:  D E Briles; S K Hollingshead; J King; A Swift; P A Braun; M K Park; L M Ferguson; M H Nahm; G S Nabors
Journal:  J Infect Dis       Date:  2000-11-08       Impact factor: 5.226

7.  Anti-PsaA and the risk of pneumococcal AOM and carriage.

Authors:  Satu Rapola; Virva Jäntti; Mervi Eerola; P Helena Mäkelä; Helena Käyhty; Terhi Kilpi
Journal:  Vaccine       Date:  2003-09-08       Impact factor: 3.641

8.  A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection.

Authors:  Keith P Klugman; Shabir A Madhi; Robin E Huebner; Robert Kohberger; Nontombi Mbelle; Nathaniel Pierce
Journal:  N Engl J Med       Date:  2003-10-02       Impact factor: 91.245

9.  Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial.

Authors:  Katherine L O'Brien; Lawrence H Moulton; Raymond Reid; Robert Weatherholtz; Jane Oski; Laura Brown; Gaurav Kumar; Alan Parkinson; Diana Hu; Jill Hackell; Ih Chang; Robert Kohberger; George Siber; Mathuram Santosham
Journal:  Lancet       Date:  2003-08-02       Impact factor: 79.321

10.  Poor potential coverage for 7-valent pneumococcal conjugate vaccine, Malawi.

Authors:  Stephen B Gordon; Stonard Kanyanda; Amanda L Walsh; Kirsty Goddard; Mas Chaponda; Victoria Atkinson; Wakisa Mulwafu; Elizabeth M Molyneux; Ed E Zijlstra; Malcolm E Molyneux; Steve M Graham
Journal:  Emerg Infect Dis       Date:  2003-06       Impact factor: 6.883

View more
  21 in total

1.  Intranasal immunization with the cholera toxin B subunit-pneumococcal surface antigen A fusion protein induces protection against colonization with Streptococcus pneumoniae and has negligible impact on the nasopharyngeal and oral microbiota of mice.

Authors:  F C Pimenta; E N Miyaji; A P M Arêas; M L S Oliveira; A L S S de Andrade; P L Ho; S K Hollingshead; L C C Leite
Journal:  Infect Immun       Date:  2006-08       Impact factor: 3.441

2.  Identification of SP1683 as a pneumococcal protein that is protective against nasopharyngeal colonization.

Authors:  Leen Moens; Philippe Hermand; Tine Wellens; Greet Wuyts; Rita Derua; Etienne Waelkens; Carine Ysebaert; Fabrice Godfroid; Xavier Bossuyt
Journal:  Hum Vaccin Immunother       Date:  2018-02-21       Impact factor: 3.452

Review 3.  Pneumonia research to reduce childhood mortality in the developing world.

Authors:  J Anthony G Scott; W Abdullah Brooks; J S Malik Peiris; Douglas Holtzman; E Kim Mulholland
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

4.  Natural Development of Antibodies against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis Protein Antigens during the First 13 Years of Life.

Authors:  Igor C Borges; Dafne C Andrade; Maria Regina A Cardoso; Jorma Toppari; Mari Vähä-Mäkilä; Jorma Ilonen; Mikael Knip; Heikki Hyöty; Riitta Veijola; Olli Simell; Tuomas Jartti; Helena Käyhty; Olli Ruuskanen; Cristiana M Nascimento-Carvalho
Journal:  Clin Vaccine Immunol       Date:  2016-11-04

5.  Diagnosis of invasive pneumococcal disease among children in Kenya with enzyme-linked immunosorbent assay for immunoglobulin G antibodies to pneumococcal surface adhesin A.

Authors:  J Anthony G Scott; Zena Mlacha; Joyce Nyiro; Salome Njenga; Pole Lewa; Jacktone Obiero; Hanningtone Otieno; Jacquelyn S Sampson; George M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  2005-10

6.  Antibodies to conserved pneumococcal antigens correlate with, but are not required for, protection against pneumococcal colonization induced by prior exposure in a mouse model.

Authors:  Krzysztof Trzcinski; Claudette Thompson; Richard Malley; Marc Lipsitch
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

7.  Maternal antibodies to pneumolysin but not to pneumococcal surface protein A delay early pneumococcal carriage in high-risk Papua New Guinean infants.

Authors:  Jacinta P Francis; Peter C Richmond; William S Pomat; Audrey Michael; Helen Keno; Suparat Phuanukoonnon; Jan B Nelson; Melissa Whinnen; Tatjana Heinrich; Wendy-Anne Smith; Susan L Prescott; Patrick G Holt; Peter M Siba; Deborah Lehmann; Anita H J van den Biggelaar
Journal:  Clin Vaccine Immunol       Date:  2009-09-23

8.  Antibodies to pneumococcal proteins PhtD, CbpA, and LytC in Filipino pregnant women and their infants in relation to pneumococcal carriage.

Authors:  Emma Holmlund; Beatriz Quiambao; Jukka Ollgren; Teija Jaakkola; Cécile Neyt; Jan Poolman; Hanna Nohynek; Helena Käyhty
Journal:  Clin Vaccine Immunol       Date:  2009-04-29

9.  Effects of ageing and gender on naturally acquired antibodies to pneumococcal capsular polysaccharides and virulence-associated proteins.

Authors:  Birgit Simell; Mika Lahdenkari; Antti Reunanen; Helena Käyhty; Merja Väkeväinen
Journal:  Clin Vaccine Immunol       Date:  2008-07-02

Review 10.  Serotype-independent pneumococcal vaccines.

Authors:  Eliane Namie Miyaji; Maria Leonor Sarno Oliveira; Eneas Carvalho; Paulo Lee Ho
Journal:  Cell Mol Life Sci       Date:  2012-12-27       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.